<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00075634</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01807</org_study_id>
    <secondary_id>NCI-2012-01807</secondary_id>
    <secondary_id>CDR0000347393</secondary_id>
    <secondary_id>COG-ADVL0215</secondary_id>
    <secondary_id>ADVL0215</secondary_id>
    <secondary_id>ADVL0215</secondary_id>
    <secondary_id>U01CA097452</secondary_id>
    <nct_id>NCT00075634</nct_id>
  </id_info>
  <brief_title>Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma</brief_title>
  <official_title>A Phase I Study of Decitabine (NSC# 127716, IND# 50733) in Combination With Doxorubicin and Cyclophosphamide in the Treatment of Relapsed or Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of decitabine when given&#xD;
      together with doxorubicin and cyclophosphamide in treating children with relapsed or&#xD;
      refractory solid tumors or neuroblastoma. Drugs used in chemotherapy, such as decitabine,&#xD;
      doxorubicin, and cyclophosphamide, work in different ways to stop tumor cells from dividing&#xD;
      so they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose of decitabine in combination with doxorubicin and&#xD;
      cyclophosphamide in children with relapsed or refractory solid tumors or neuroblastoma.&#xD;
&#xD;
      II. Determine the toxic effects of this regimen in these patients. III. Determine whether&#xD;
      decitabine induces tumor caspase-8 demethylation and expression in these patients.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the pharmacokinetics of low-dose decitabine in these patients. II. Determine the&#xD;
      biological and clinical response in patients treated with this regimen.&#xD;
&#xD;
      III. Compare patterns of peripheral blood gene expression, using gene expression profiling,&#xD;
      in patients before and after treatment with decitabine.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of decitabine.&#xD;
&#xD;
      PART A (solid tumor patients): Patients receive decitabine IV over 1 hour on days 0-6 and&#xD;
      doxorubicin IV over 15 minutes and cyclophosphamide IV over 1 hour on day 7. Patients then&#xD;
      receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 8 and continuing until blood&#xD;
      counts recover OR pegfilgrastim SC once on day 8 or 9*. Treatment repeats every 28 days for&#xD;
      up to 12 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of decitabine until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      NOTE: *For patients &gt; 45 kg&#xD;
&#xD;
      PART B (neuroblastoma patients): Once the MTD is determined for part A, patients are treated&#xD;
      as in part A at the MTD.&#xD;
&#xD;
      Patients are followed at 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD of decitabine, based on incidence of DLT graded according to NCI CTCAE version 3.0 (Part A)</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Caspase-8 expression in bone marrow or tumor biopsy samples (Part B)</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to 56 days</time_frame>
    <description>Confidence intervals will be reported in addition to the estimated response rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of apoptotic cells as assessed by a TUNEL assay</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>A sign test or other appropriate nonparametric test may be used to assess whether there was an increase in the percent of apoptotic cells after treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Recurrent Neuroblastoma</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PART A (solid tumor patients): Patients receive decitabine IV over 1 hour on days 0-6 and doxorubicin IV over 15 minutes and cyclophosphamide IV over 1 hour on day 7. Patients then receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 8 and continuing until blood counts recover OR pegfilgrastim SC once on day 8 or 9*. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.&#xD;
PART B (neuroblastoma patients): Once the MTD is determined for part A, patients are treated as in part A at the MTD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>decitabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>5-aza-dCyd</other_name>
    <other_name>5AZA</other_name>
    <other_name>DAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>ADM</other_name>
    <other_name>ADR</other_name>
    <other_name>Adria</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Filgrastim SD-01</other_name>
    <other_name>GCSF-SD01</other_name>
    <other_name>Neulasta</other_name>
    <other_name>SD-01 sustained duration G-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of either of the following:&#xD;
&#xD;
               -  Solid tumor (part A)&#xD;
&#xD;
                    -  No lymphoma&#xD;
&#xD;
               -  Neuroblastoma (part B)&#xD;
&#xD;
                    -  Original diagnosis may be based on elevated urine vanillylmandelic acid&#xD;
                       (VMA) and homovanillic acid (HVA) and bone marrow examination&#xD;
&#xD;
                    -  Accessible disease by bone marrow aspirate or tumor biopsy&#xD;
&#xD;
                         -  No laparotomy, thoracotomy, endoscopy, or craniotomy for biopsy&#xD;
&#xD;
          -  No known curative therapy OR therapy proven to prolong survival with an acceptable&#xD;
             quality of life available&#xD;
&#xD;
          -  No known brain or spinal cord metastases&#xD;
&#xD;
          -  No CNS tumors&#xD;
&#xD;
          -  Performance status - Karnofsky 50-100% (patients 11 to 21 years of age)&#xD;
&#xD;
          -  Performance status - Lansky 50-100% (patients ≤ 10 years of age)&#xD;
&#xD;
          -  Parts A and B without bone marrow infiltration:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,000/mm^3&#xD;
&#xD;
               -  Platelet count ≥ 100,000/mm^3 (transfusion independent)&#xD;
&#xD;
          -  Part B with bone marrow infiltration (i.e., tumor metastatic to bone marrow with&#xD;
             granulocytopenia, anemia, and/or thrombocytopenia):&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 750/mm^3&#xD;
&#xD;
               -  Platelet count ≥ 50,000/mm^3 (transfusion independent)&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL (transfusion allowed)&#xD;
&#xD;
          -  No sickle cell anemia&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  ALT ≤ 5 times upper limit of normal&#xD;
&#xD;
          -  No significant hepatic dysfunction that would compromise the tolerability of&#xD;
             decitabine or interfere with study procedures or results&#xD;
&#xD;
          -  Creatinine based on age as follows:&#xD;
&#xD;
               -  ≤ 0.8 mg/dL (5 years of age and under)&#xD;
&#xD;
               -  ≤ 1.0 mg/dL (6 to 10 years of age)&#xD;
&#xD;
               -  ≤ 1.2 mg/dL (11 to 15 years of age)&#xD;
&#xD;
               -  ≤ 1.5 mg/dL (16 to 21 years of age)&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min&#xD;
&#xD;
          -  No significant renal dysfunction that would compromise the tolerability of decitabine&#xD;
             or interfere with study procedures or results&#xD;
&#xD;
          -  Shortening fraction ≥ 28% by echocardiogram&#xD;
&#xD;
          -  Ejection fraction of ≥ 45% by MUGA&#xD;
&#xD;
          -  No significant pulmonary dysfunction that would compromise the tolerability of&#xD;
             decitabine or interfere with study procedures or results&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior allergic reaction attributed to compounds of similar chemical or biological&#xD;
             composition to agents used in this study&#xD;
&#xD;
          -  No uncontrolled serious infection&#xD;
&#xD;
          -  No significant end-organ dysfunction that would compromise the tolerability of&#xD;
             decitabine or interfere with study procedures or results&#xD;
&#xD;
          -  Recovered from prior immunotherapy&#xD;
&#xD;
          -  At least 7 days since prior biologic therapy&#xD;
&#xD;
          -  More than 1 week since prior growth factor therapy (2 weeks for pegfilgrastim)&#xD;
&#xD;
          -  More than 2 weeks since prior epoetin alfa&#xD;
&#xD;
          -  At least 6 months since prior autologous stem cell transplantation&#xD;
&#xD;
          -  At least 6 months since prior allogeneic bone marrow transplantation&#xD;
&#xD;
               -  Patients must have full organ recovery and no evidence of graft-versus-host&#xD;
                  disease&#xD;
&#xD;
          -  No concurrent immunomodulating agents&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
          -  No concurrent epoetin alfa&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
          -  More than 2 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  Prior total lifetime cumulative anthracycline dose ≤ 450 mg/m^2 of doxorubicin or&#xD;
             equivalent&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  No concurrent hydroxyurea&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  More than 2 weeks since prior local palliative small port radiotherapy&#xD;
&#xD;
          -  More than 6 months since prior substantial bone marrow irradiation (e.g.,&#xD;
             cranio-spinal irradiation, total body irradiation, or hemi-pelvic irradiation)&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  Concurrent oral iron supplementation for patients with a known iron deficiency or a&#xD;
             microcytic hypochromic anemia allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rani George</last_name>
    <role>Principal Investigator</role>
    <affiliation>COG Phase I Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Oncology Group</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006-3776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>January 9, 2004</study_first_submitted>
  <study_first_submitted_qc>January 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2004</study_first_posted>
  <last_update_submitted>September 27, 2013</last_update_submitted>
  <last_update_submitted_qc>September 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

